Jefferies 2014 Global Healthcare Conference

Transcription

1 Jefferies 2014 Global Healthcare Conference June 4 th, 2014

2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. This includes all statements concerning or relating to our ability to improve treatment and outcomes to reduce costs, our new product development goals and our expectations regarding growth in various markets, organic growth, operational execution and reduced leverage. Such forward-looking statements are estimates reflecting management s best judgment based upon current information and involve a number of risks and uncertainties. Actual results and the timing of certain events could differ materially from those projected or contemplated by the forward-looking statements due to numerous factors, including without limitation, our ability to successfully acquire and integrate our acquisitions and to recognize the expected benefits of restructuring and new business activities; our exposure to changes in interest rates and foreign currency exchange rates; our ability to successfully develop and commercialize products and services; the market acceptance of our products and services; continued acceptance of health information solutions by payers, providers and patients; our ability to develop enhanced health information solutions through the integrated use of innovative diagnostic and monitoring devices and to recognize the expected benefits of this strategy; the impact of healthcare reform legislation, as well as future reform initiatives; the content and timing of regulatory decisions and actions, including the results and consequences of FDA inspections and the OIG subpoena, as well as the impact of changes in reimbursement policy and budgetary constraints, both in the United States and abroad; the effect of pending and future legal proceedings on our financial performance and the risks and uncertainties described in our periodic reports filed with the Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2013, as well as in our Quarterly Reports on Form 10-Q. Our Company undertakes no obligation to update forward-looking statements. Projections, guidance and other forward-looking statements included in this presentation were issued on, and as of, June 4, We are not reaffirming or confirming the continued validity of any of these projections, guidance or other statements by inclusion in this presentation. The Company undertakes no obligation to update forwarding-looking statements, including projections or guidance, included herein. 2

3 Investor Highlights Global leader in near-patient diagnostics. Well positioned for enhanced organic growth from geographic expansion and new product launches. Company s formation substantially complete. Excellent free cash flow with further improvement expected. Significant opportunity to improve operating expense leverage. Balance sheet deleveraging underway with near-term transactions expected. 3

4 The Alere Mission Creates Value Alere empowers individuals to take greater control of their health under the supervision of their healthcare providers. We enable» Earlier interventions» Fewer hospitalizations» Reduced healthcare costs» Better coordination between patients, payers and providers» More personalized treatment» Improved healthcare outcomes and help address the global crisis in national budgets 4

5 World s Leading Provider of POC Diagnostics Revenue by Therapeutic Area 1 Revenue by Geographic Region 1 Global leader in near-patient diagnostics for Cardiology, Infectious Disease and Toxicology Revenues of $3.0 Billion, EBITDA 2 of $622 Million. Revenues heavily weighted to recurring consumable sales in acute or event-driven settings. Direct sales infrastructure in all major worldwide markets supports our rapid growth in emerging markets. Integration of diagnostics with care management software helps providers achieve better patient outcomes and reduced costs, supporting the needs of at-risk healthcare providers. Notes: (1) Breakout based on 2013 product and service revenues. (2) EBITDA excluding restructuring charges and acquisition expenses. This is a non- GAAP measure. For a reconciliation to GAAP earnings per share, please visit 5

6 Revenue & Adjusted EBITDA Revenue ($MM) Adjusted EBITDA ($MM) 1 Notes: (1) EBITDA excluding restructuring charges and acquisition expenses incurred in each respective period. This is a non-gaap measure. For a reconciliation to GAAP earnings per share, please visit 6

7 Our Approach to Managing Chronic Conditions We manage the process that leads to health behavior change. Diagnostic Devices All Patient Data Collected Through Health Information Exchange Data Interpretation- Validated Rules Engine Behavioral Change- Coaching & Clinical Decision Support Ability to Improve Health Outcomes 7

8 Our Worldwide Presence Our approach and product portfolio provide opportunities for growth around the world. Alere solutions are available in more than 100 countries, with a direct presence in 36 countries. Alere Location 8

9 Positioned for Growth in China Increased disease burden in China due to an aging population, urbanization and changes in dietary habits. Alere Triage BNP Accelerate HF treatment decisions Risk stratify ACS at the point of care Afinion AS100 Analyzer Provides lab-quality reading of HbA1c at the point of care Simple and fast testing, regardless of sample size ABON Hepatitis B Virus Test Average accuracy of 98% 15 minutes to get results of 5 indicators 9

10 Positioned for Growth in India The incidence of cardiovascular disease and diabetes is increasing dramatically in India. epoc Blood Analysis System Broadest blood analysis menu on a single test card Used to detect electrolyte disorders, metabolic disorders and renal injuries Alere Triage Cardiac Panel Quantitative measurements of Myoglobin, CK-MB and Troponin I Aid in the diagnosis of myocardial infarction (injury) Afinion HbA1c Test Used to monitor metabolic control in patients with diabetes Contains all reagents necessary for the measurement of glycated hemoglobin 10

11 Positioned for Growth in Africa Incidence of infectious diseases such as HIV continue to impact a significant portion of the African population. Alere Determine HIV HIV screening test of choice in most country testing algorithms Significant YOY increase in volumes over last 5 years Alere CD4 World s first device to provide absolute CD4 count at the point of care DataPoint connectivity via mobile network Alere q HIV Transformational POC MDx platform First target is HIV detection, Early Infant Diagnosis and Viral Load monitoring 11

12 Positioned for Growth in Latin America Non-communicable chronic diseases have replaced communicable diseases as the major cause of burden of illness in South America. NycoCard HbA1c Test Provides lab-quality reading of HbA1c at the point of care Simple and fast testing, regardless of sample size epoc Blood Analysis System Broadest blood analysis menu on a single test card Used to detect electrolyte disorders, metabolic disorders and renal injuries Alere Triage Cardiac Panel Quantitative measurements of Myoglobin, CK-MB and Troponin I Aid in the diagnosis of Myocardial infarction (injury) 12

13 Solid Foundation for Growth in the U.S. Recovery of Triage sales, increasing demand for roadside toxicology testing and launch of rapid molecular platforms will drive growth. Alere Triage MeterPro Leading diagnostic platform that helps physicians identify several critical health conditions Alere DDS 2 Portable roadside system designed for rapid screening for drugs of abuse in oral fluid Alere i Molecular platform for acute, near-patient testing offering significant improvements over today s lateral flow technology Alere LDX Provides quick and easy screening for heart disease at the point of care, allowing for responsive treatment 13

14 Our Three-Point Plan With company formation essentially complete, we established a three point plan to unlock the value of our assets and reward shareholders. 1. Drive organic revenue growth rates to historically high levels in the POC diagnostics business. 2. Continued improvement in operational execution to generate predictable earnings growth and sustainable, strong cash flow. 3. Deleverage the balance sheet to 3.0x Debt to EBITDA1 by the end of Notes: (1) EBITDA excluding restructuring charges and acquisition expenses incurred in each respective period. This is a non-gaap measure. For a reconciliation to GAAP earnings per share, please visit 14

15 Re-Establishment of Historic Organic Revenue Growth Rates in Point of Care Re-establish historic organic revenue growth rates through a combination of growth in existing businesses, new product launches and further penetration of new geographic markets. Key growth drivers: Increasing growth rate of base businesses as we overcome Triage supply challenges and continue to penetrate ACOs with our integrated product and service offerings. Current product launches such as the CD4 Analyzer, Alere i and q, additional markers on epoc, as well as numerous pending launches will drive higher growth rates. Expanding markets in Asia, Latin America, and Africa will continue to underpin long term growth. Annual Organic Revenue Growth* Quarterly LTM Organic Revenue Growth* 8% 6% 4% 7.5% 5.2% 6.2% 4.8% 5.1% 8% 6% 4% 4.8% 4.0% 5.8% 6.0% 5.1% 2% 2% 0% % LTM Q LTM Q LTM Q LTM Q LTM Q *Organic Revenue Growth as Measured for the Professional Diagnostics Business Unit only, excluding the impacts of North American flu and Triage revenues. 15

16 Continued Improvement in Operational Execution Simplify our corporate structure and improve operational execution to generate dependable, long-term cash flow. Actions Taken or Underway: Standardizing key business processes and globalizing shared services. Relocating support functions to lower-cost environments and reducing manufacturing costs through automation. Creation of our first dedicated COO role, with a firm mandate to improve on our execution. Annual, Adjusted Operating Expense % Quarterly, Adjusted Operating Expense % 36% 35% 34% 33% 32% 35.8% 34.6% 34.0% 34.3% 33.4% % 35% 35% 34% 34% 34% 34% 34% 34.8% 34.7% 34.4% 34.1% 34.0% Q Q Q Q Q

17 Deleveraging the Balance Sheet Utilize excess cash flow from operations, a reduced acquisition pace and divestitures of non-core operations to support deleveraging to 3.0x Debt to EBITDA 1 by the end of Actions Taken or Underway: Engaged in active and ongoing discussions with multiple parties concerning transactions for several non-core businesses. Maintaining a balance between paying down debt and incurring excessive earnings dilution or diminishing our organic growth rate. Cash flow generation and earnings growth in our core businesses have begun to improve. Annual Net Debt to EBITDA 1 Ratio Quarterly Net Debt to EBITDA 1 Ratio Q Q Q Q Q Notes: (1) EBITDA excluding restructuring charges and acquisition expenses incurred in each respective period. This is a non-gaap measure. For a reconciliation to GAAP earnings per share, please visit 17

18 Three Point Plan Metrics through 2015 Organic Revenue Growth Expect mid-single digit organic revenue growth for 2013 to expand over the next two years to higher single digit organic growth by Operational Execution Our expense reduction initiatives will allow us to exit 2014 at an Adjusted SG&A rate of 28%, down from the full year 2012 rate of 30.4%. Expect 28% to be our full year 2015 Adjusted SG&A rate. Expect to hold Adjusted R&D spending at our current run rate of approximately $155 million for 2014 and Deleveraging Reduce our debt leverage ratio, achieving 3.0x Net Debt to EBITDA 1 by the end of 2015 without excessively compromising our core business or our longer term growth opportunities. Notes: (1) EBITDA excluding restructuring charges and acquisition expenses incurred in each respective period. This is a non-gaap measure. For a reconciliation to GAAP earnings per share, please visit 18

19 Beyond 2015 Organic Revenue Growth Sustain higher single digit growth. Increasing contribution from emerging products and geographies will provide an opportunity to achieve higher growth in some years. Operational Execution Seek further expense leverage and integration opportunities to reduce Adjusted SG&A below 28% on an annual basis in future years. Continued controls around R&D spending, split evenly between existing and breakthrough platforms. Commitment to annual EPS growth and predictability of earnings. Deleveraging Continued deleveraging through use of cash flow. 19

20 Investor Summary Global leader in near patient diagnostics. Well positioned for enhanced organic growth from geographic expansion and new product launches. Company s formation substantially complete. Excellent free cash flow with further improvement expected. Significant opportunity to improve operating expense leverage. Balance sheet deleveraging underway with near-term transactions expected. 20

21 Better Information. Better Decisions. Better Health